Top-end interventions featured in Scottish surgery guarantees:
This article was originally published in Clinica
Executive Summary
Scottish plans to end the so-called "hidden waiting lists" of surgery patients should provide a boost to the most specialised interventions, some of which have, until now, been excluded from the lists altogether. So said cabinet secretary for health and wellbeing, Nicola Sturgeon, in an announcement to parliament concerning the new surgery management system that will replace Availabilty Status Codes (ASCs) by the end of this year. "Patients will no longer be excluded from waiting time guarantees because their treatment is considered either of low clinical priority or too highly specialised." She acknowledged that some patients have been facing waits of "months and, in some cases, years" for treatment; the new system will also be "fully transparent and open to public scrutiny".
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.